TY - JOUR
T1 - Novel risk assessment for the intensity of conditioning regimen in older patients
AU - Akahoshi, Yu
AU - Tada, Yuma
AU - Sakaida, Emiko
AU - Kusuda, MacHiko
AU - Doki, Noriko
AU - Uchida, Naoyuki
AU - Fukuda, Takahiro
AU - Tanaka, Masatsugu
AU - Sawa, Masashi
AU - Katayama, Yuta
AU - Matsuoka, Ken Ichi
AU - Ozawa, Yukiyasu
AU - Onizuka, Makoto
AU - Kanda, Junya
AU - Kanda, Yoshinobu
AU - Atsuta, Yoshiko
AU - Nakasone, Hideki
N1 - Publisher Copyright:
© 2023 by The American Society of Hematology.
PY - 2023/9/12
Y1 - 2023/9/12
N2 - Reduced-intensity conditioning (RIC) regimens have long-term outcomes that are generally comparable with those of myeloablative conditioning (MAC) because of a lower risk of nonrelapse mortality (NRM) but a higher risk of relapse. However, it is unclear how we should select the conditioning intensity in individual cases. We propose the risk assessment for the intensity of conditioning regimen in elderly patients (RICE) score. We retrospectively analyzed 6147 recipients aged 50 to 69 years using a Japanese registry database. Based on the interaction analyses, advanced age (≥60 years), hematopoietic cell transplantation-specific comorbidity index (≥2), and umbilical cord blood were used to design a scoring system to predict the difference in an individual patient's risk of NRM between MAC and RIC: the RICE score, which is the sum of the 3 factors. Zero or 1 implies low RICE score and 2 or 3, high RICE score. In multivariate analyses, RIC was significantly associated with a decreased risk of NRM in patients with a high RICE score (training cohort: hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.60-0.90; P = .003; validation cohort: HR, 0.57; 95% CI, 0.43-0.77; P < .001). In contrast, we found no significant differences in NRM between MAC and RIC in patients with a low RICE score (training cohort: HR, 0.99; 95% CI, 0.85-1.15; P = .860; validation cohort: HR, 0.81; 95% CI, 0.66-1.01; P = .061). In summary, a new and simple scoring system, the RICE score, appears to be useful for personalizing the conditioning intensity and could improve transplant outcomes in older patients.
AB - Reduced-intensity conditioning (RIC) regimens have long-term outcomes that are generally comparable with those of myeloablative conditioning (MAC) because of a lower risk of nonrelapse mortality (NRM) but a higher risk of relapse. However, it is unclear how we should select the conditioning intensity in individual cases. We propose the risk assessment for the intensity of conditioning regimen in elderly patients (RICE) score. We retrospectively analyzed 6147 recipients aged 50 to 69 years using a Japanese registry database. Based on the interaction analyses, advanced age (≥60 years), hematopoietic cell transplantation-specific comorbidity index (≥2), and umbilical cord blood were used to design a scoring system to predict the difference in an individual patient's risk of NRM between MAC and RIC: the RICE score, which is the sum of the 3 factors. Zero or 1 implies low RICE score and 2 or 3, high RICE score. In multivariate analyses, RIC was significantly associated with a decreased risk of NRM in patients with a high RICE score (training cohort: hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.60-0.90; P = .003; validation cohort: HR, 0.57; 95% CI, 0.43-0.77; P < .001). In contrast, we found no significant differences in NRM between MAC and RIC in patients with a low RICE score (training cohort: HR, 0.99; 95% CI, 0.85-1.15; P = .860; validation cohort: HR, 0.81; 95% CI, 0.66-1.01; P = .061). In summary, a new and simple scoring system, the RICE score, appears to be useful for personalizing the conditioning intensity and could improve transplant outcomes in older patients.
UR - http://www.scopus.com/inward/record.url?scp=85171616282&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85171616282&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2022008706
DO - 10.1182/bloodadvances.2022008706
M3 - Article
C2 - 36508283
AN - SCOPUS:85171616282
SN - 2473-9529
VL - 7
SP - 4738
EP - 4747
JO - Blood Advances
JF - Blood Advances
IS - 17
ER -